Henlius Biotech Initiates Phase III Study for HLX22 in Gastric Cancer Treatment
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the dosing of the first patient...
China’s NHC Sets Sights on Enhancing Grassroots Drug Management and Access
The National Health Commission (NHC) has issued a set of opinions designed to accelerate the...
MicroPort Scientific Corp.’s BonaFire Receives NMPA Approval as First Whole-Body MRI Safety Pacing Electrode Lead
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...
Base Therapeutics’ NK510 Receives US FDA Clearance for Advanced Solid Tumor Studies
Shanghai-based cell therapy specialist Base Therapeutics has achieved clearance from the US Food and Drug...
Merck KGaA Partners with NTU Singapore to Drive Digital Transformation with Trust Technology
Merck KGaA (NYSE: MRK) has entered into a Memorandum of Understanding with the Digital Trust...
GSK’s Arexvy Receives MHLW Approval for Expanded RSV Indication in Japan
UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that Japan’s Ministry of Health, Labour...
China Resources Double-Crane Gets NMPA Approval for Semaglutide Biosimilar Clinical Trial
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced that it has received clinical...
J&J Submits sBLA to FDA for Subcutaneous Tremfya Regimen in Ulcerative Colitis
Johnson & Johnson (J&J; NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to...
Servier’s Vorasidenib Approved in Boao Lecheng Medical Zone for Diffuse Gliomas
French pharmaceutical company Servier’s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor,...
Leads Biolabs’ LBL-024 Earns FDA Orphan Drug Designation for Neuroendocrine Cancer
China-based Leads Biolabs Inc. has announced that it has obtained Orphan Drug Designation (ODD) from...
Signet Therapeutics’ SIGX1094 Earns Orphan Drug Designation for Gastric Cancer from FDA
China-based Signet Therapeutics has announced that it has received Orphan Drug Designation (ODD) from the...
Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange
China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to...
MSD Partners with Cancer Foundation of China for HPV Vaccine Donation Program
Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a donation agreement with the...
Sciwind Biosciences’ Ecnoglutide Accepted for Review by China’s NMPA for Type 2 Diabetes
China-based Sciwind Biosciences Co., Ltd has announced that the National Medical Products Administration (NMPA) has...
Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation
On November 22, China General Technology (Group) Holding released three official announcements through its official...
Leman Biotech Enters Zhongshan Life Science Park to Accelerate CAR-T Innovation
Innovative biotechnology company Leman Biotech, focused on cutting-edge cell therapy technology, has announced its official...
BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline
On November 22, 2024, BRL Medicine Inc. announced the completion of nearly 200 million yuan...
Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies
On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China,...
HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a milestone payment...
First Patient Dosed in Abbisko’s Phase II Trial of ABSK061 and ABSK043 in FGFR2/3 Altered Tumors
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing in...